Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
- Companies
- Company details
Sigma-Tau
The worldwide leader in carnitine and metabolic researchThe company in detail
Summary
Sigma-Tau, a research-based Italian pharmaceutical company with subsidiaries worldwide, was founded in 1957, and is the worldwide pioneer in carnitine and metabolic research, and ranks among the top 25 niche companies in the world in patent activity.
R&D
To view this information, you must subscribe to Partneringtools.
Partnerships
To view this information, you must subscribe to Partneringtools.
Deals
To view this information, you must subscribe to Partneringtools.
Senior management
To view this information, you must subscribe to Partneringtools.
Head office
To view this information, you must subscribe to Partneringtools.
Related companies
Related categories
- Industry sector
- Biotechnology / Human therapeutics
- Biotechnology / Other
- Drug discovery
- Pharmaceutical / Prescription
- Pharmaceutical / OTC/Non-Prescription
- Therapeutic target
- Blood and forming organs
- Blood and forming organs / Blood disorders / Blood disorders (other)
- Cardiovascular
- Central Nervous System
- Central Nervous System / CNS (other)
- Metabolism
- Metabolism / Diabetes type I
- Oncology
- Oncology / Cancer (other)
- Oncology / Treatments / Chemotherapy
- Other therapeutic
- Other therapeutic / Other
- Other therapeutic / Dietetic
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us